At the 44th Annual J.P. Morgan Healthcare Conference, Edgewise Therapeutics CEO Kevin Koch detailed substantial progress across its muscle disease portfolio. In 2025 the company completed enrollment of its GRAND CANYON pivotal trial in Becker muscular dystrophy and expects top-line data by year-end. Its Duchenne programs, LYNX (steroid-experienced patients) and FOX (gene therapy-experienced patients), continue with 60 participants on study; interim analysis later this year will assess rate-of-decline reductions. For its cardiovascular asset EDG-7500, the company reported positive safety and tolerability data in the CIRRUS-HCM Phase 2 study, with Parts B and C completed and Part D interim favorability announced in December 2025.

Edgewise strengthened its balance sheet in April 2025 with approximately $200 million net proceeds from a public follow-on offering, funding its skeletal and cardiac programs. In addition to GRAND CANYON enrollment, the company achieved positive open-label extension results in the MESA Phase 2 trial of sevasemten in Becker patients. In Duchenne, LYNX showed improvement in Stride Velocity 95th Centile and North Star Ambulatory Assessment endpoints at a 10 mg dose, while FOX supported potential functional decline reduction at the same dose. EDG-15400 entered first-in-human Phase 1 studies with single and multiple ascending dose cohorts initiated in healthy volunteers.

Edgewise’s priorities for the coming year include reporting CIRRUS-HCM 12-week data for obstructive and nonobstructive hypertrophic cardiomyopathy in H1 2026, and initiating Phase 3 trials for EDG-7500 in HCM in H2. Sevasemten’s GRAND CANYON global cohort data are slated for Q4 2026, with plans to file a U.S. New Drug Application in H1 2027. The company will also finalize Phase 3 design for Duchenne muscular dystrophy in the second half of 2026, while advancing EDG-15400 into Phase 2 heart failure trials, with results expected by mid-2027.

As of January 2026, Edgewise reports a robust cash runway from its $200 million April 2025 financing, supporting multiple near-term catalysts across three clinical-stage assets. The balance sheet strength enables simultaneous execution of pivotal and early development programs without the need for immediate additional capital. Management emphasizes disciplined resource allocation to maximize value creation as key datasets read out over the next 18 months.